Waldenström macroglobulinemia: From biology to treatment

Expert Review of Hematology

Volumn 7, Issue 1, 2014, Pages 157-168

  Sahin, Ilyas ^a   Leblebjian, Houry ^a   Treon, Steven P ^a   Ghobrial, Irene M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

biology; Brutons tyrosine; kinase; MYD88; treatment; Waldenstr m macroglobulinemia

Indexed keywords

BORTEZOMIB; BRUTON TYROSINE KINASE INHIBITOR; CARFILZOMIB; ENZASTAURIN; EVEROLIMUS; HISTONE DEACETYLASE INHIBITOR; IBRUTINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN M; IMMUNOMODULATING AGENT; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MYELOID DIFFERENTIATION FACTOR 88; NUCLEOSIDE ANALOG; PANOBINOSTAT; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; POMALIDOMIDE; PROTEASOME INHIBITOR; PROTEIN KINASE B; RITUXIMAB; STAT PROTEIN;

ACROCYANOSIS; ASYMPTOMATIC DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; B LYMPHOCYTE; BLOOD CELL COUNT; BLOOD SMEAR; BLOOD VISCOSITY; CLINICAL FEATURE; COOMBS TEST; COPY NUMBER VARIATION; CYTOGENETICS; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; EPIGENETICS; FAMILIAL DISEASE; FAMILY HISTORY; FATIGUE; GENE EXPRESSION PROFILING; GENE SEQUENCE; HEPATOSPLENOMEGALY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPHENOTYPING; LABORATORY TEST; LIVER FUNCTION TEST; LYMPHADENOPATHY; MAINTENANCE THERAPY; MONOCLONAL IMMUNOGLOBULINEMIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; RASH; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL; WALDENSTROEM MACROGLOBULINEMIA;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHROMOSOME ABERRATIONS; GENE EXPRESSION PROFILING; HUMANS; IMMUNOGLOBULIN M; IMMUNOLOGIC FACTORS; PROTEASOME INHIBITORS; PROTEIN KINASE INHIBITORS; PROTEOMICS; WALDENSTROM MACROGLOBULINEMIA;

EID: 84893245442     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2014.871494     Document Type: Review

References (116)

1. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al. Waldenstrom's macroglobulinemia: clinical features, complications and management. J Clin Oncol 2000;18(1):214-26
2. Ghobrial IM, Gertz MA, Fonseca R. Waldenstrom macroglobulinaemia. Lancet Oncol 2003;4(11):679-85
3. Kyle RA, Anderson KC. A tribute to Jan Gosta Waldenstrom. Blood 1997;89(12): 4245-7
4. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30(2):110-15
5. Dimopoulos MA, Kyle RA, Anagnostopoulos A, et al. Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol 2005;23: 1564-77
6. Herrinton LJ, Weiss NS. Incidence of Waldenstrom's macroglobulinemia. Blood 1993;82(10):3148-50
7. Jemal A, Murray T, Ward E, et al. Cancer statistics. CA Cancer J Clin 2005;55(1): 10-30
8. American Cancer Society. Cancer Facts & Figures 2012. American Cancer Society; Atlanta, GA, USA: 2012
9. Sahota SS, Forconi F, Ottensmeier CH, et al. Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. Blood 2002;100(4):1505-7
10. Schop RF, Kuehl WM, Van Wier SA, et al. Waldenstrom macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood 2002;100(8):2996-3001
11. Braggio E, Keats JJ, Leleu X, et al. High-resolution genomic analysis in Waldenstrom's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas. Clin Lymphoma Myeloma 2009;9(1):39-42
12. Chang H, Qi X, Xu W, et al. Analysis of 6q deletion in Waldenstrom macroglobulinemia. Eur J Haematol 2007; 79(3):244-7
13. Braggio E, Keats JJ, Leleu X, et al. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res 2009;69(8): 3579-88
14. Gutierrez NC, Ocio EM, De Las Rivas J, et al. Gene expression profiling of B lymphocytes and plasma cells from Waldenstrom's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia 2007; 21(3):541-9
15. Poulain S, Braggio E, Roumier C, et al. High-throughput genomic analysis in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011;11(1): 106-8
16. Turner CA Jr, Mack DH, Davis MM. BLIMP-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin- secreting cells. Cell 1994;77(2):297-306
17. Nguyen-Khac F, Lambert J, Chapiro E, et al. Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstrom's macroglobulinemia. Haematologica 2013; 98(4):649-54
18. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N Engl J Med 2012;367(9):826-33
19. Xu L, Hunter ZR, Yang G, et al. MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 2013; 121(11):2051-8
20. Varettoni M, Arcaini L, Zibellini S, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. Blood 2013; 121(13):2522-8
21. Gachard N, Parrens M, Soubeyran I, et al. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstrom macroglobulinemia/lymphoplasmacytic lymphomas. Leukemia 2013;27(1):183-9
22. Jimenez C, Sebastian E, Chillon MC, et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom's macroglobulinemia. Leukemia 2013;27(8):1722-8
23. Poulain S, Roumier C, Decambron A, et al. MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood 2013;121(22): 4504-11
24. Mori N, Ohwashi M, Yoshinaga K, et al. L265P Mutation of the MYD88 Gene Is Frequent in Waldenstrom's Macroglobulinemia and Its Absence in Myeloma. PLoS ONE 2013;8(11):e80088
25. Ondrejka SL, Lin JJ, Warden DW, et al. MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders. Am J Clin Pathol 2013;140(3):387-94
26. Landgren O, Staudt L. MYD88 L265P somatic mutation in IgM MGUS. N Engl J Med 2012;367(23):2255-6
27. Muzio M, Ni J, Feng P, Dixit VM. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 1997;278(5343): 1612-15
28. Wesche H, Henzel WJ, Shillinglaw W, et al. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity 1997;7(6):837-47
29. Bianchi G, Sacco A, Kumar S, et al. Candidate genes of Waldenstrom's macroglobulinemia: current evidence and research. Appl Clin Genet 2013;6:33-42
30. Hunter Z, Xu L, Yang G, et al. The genomic landscape of Waldenstom's Macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 2013
31. Roccaro AM, Sacco A, Jimenez C, et al. A novel activating mutation of CXCR4 plays a crucial role in waldenstrom macroglobulinemia biology. Blood (ASH annual meeting abstracts) 2013;122(21):272
32. Cao Y, Xu L, Liu X, et al. Whole genome sequencing identifies recurring somatic mutations in the C-Terminal domain of CXCR4, including a gain of function mutation in waldenstrom's macroglobinemia. Blood (ASH annual meeting abstracts) 2013;120(21):2715
33. Esteller M. Epigenetics provides a new generation of oncogenes and tumoursuppressor genes. Br J Cancer 2006;94(2): 179-183
34. Esteller M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer 2007; 96(Suppl):R26-30
35. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358(11):1148-59
36. Roccaro AM, Sacco A, Chen C, et al. MicroRNA expression in the biology, prognosis and therapy of Waldenstrom macroglobulinemia. Blood 2009;113(18): 4391-402
37. Sacco A, Ghobrial IM, Roccaro AM. Epigenetics in Waldenstrom's macroglobulinemia. Epigenomics 2010;2(5): 691-6
38. Calin GA, Cimmino A, Fabbri M, et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A 2008;105(13):5166-71
39. Chng WJ, Schop RF, Price-Troska T, et al. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood 2006;108(8):2755-63
40. Trojani A, Greco A, Tedeschi A, et al. Microarray demonstrates different gene expression profiling signatures between Waldenstrom macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Clin Lymphoma Myeloma Leuk 2013;13(2):208-10
41. Hatjiharissi E, Ngo H, Leontovich AA, et al. Proteomic analysis of waldenstrom macroglobulinemia. Cancer Res 2007;67(8): 3777-84
42. Gottipati S, Rao NL, Fung-Leung WP. IRAK1: a critical signaling mediator of innate immunity. Cell Signal 2008;20(2): 269-76
43. Yang G, Zhou Y, Liu X, et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia. Blood 2013;122(7): 1222-32
44. Treon SP, Hunter ZR. A new era for Waldenstrom macroglobulinemia: MYD88 L265P. Blood 2013;121(22): 4434-6
45. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2(7):489-501
46. Leleu X, Jia X, Runnels J, et al. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood 2007;110(13):4417-26
47. Sacco A, Roccaro A, Ghobrial IM. Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia. Oncotarget 2010;1(7):578-82
48. Yang G, Liu X, Zhou Y, et al. PI3K/AKT Pathway Is Activated By MYD88 L265P and Use Of PI3K-Delta Inhibitors Induces Robust Tumor Cell Killing In Waldenstrom's Macroglobulinemia. Blood (ASH annual meeting abstracts) 2013; 122(21):4255
49. Roccaro AM, Sacco A, Husu EN, et al. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood 2010;115(3):559-69
50. Hodge LS, Ansell SM. Jak/Stat pathway in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011;11(1): 112-14
51. Elsawa SF, Novak AJ, Ziesmer SC, et al. Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity. Blood 2011;118(20):5540-9
52. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004;18(18): 2195-224
53. Roccaro AM, Leleu X, Sacco A, et al. Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood 2008;111(9): 4752-63
54. Roccaro AM, Sacco A, Aujay M, et al. Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. Blood 2010;115(20): 4051-60
55. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 2009; 27(23):3830-5
56. Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom Macroglobulinemia. Am J Hematol 2010; 85(9):670-4
57. Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010; 28(8):1422-8
58. Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003;102(10):3759-64
59. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005;106(3):812-17
60. Varettoni M, Zibellini S, Arcaini L, et al. MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance. Blood 2013; 122(13):2284-5
61. Kyle RA, Garton JP. The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc 1987;62(8):719-31
62. Leleu X, Moreau AS, Weller E, et al. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leuk Lymphoma 2008;49(6):1104-7
63. Schop RF, Van Wier SA, Xu R, et al. 6q deletion discriminates Waldenstrom macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Cancer Genet Cytogenet 2006;169(2):150-3
64. Treon SP, Hunter ZR, Aggarwal A, et al. Characterization of familial Waldenstrom's macroglobulinemia. Ann Oncol 2006;17(3): 488-94
65. Kristinsson SY, Bjorkholm M, Goldin LR, et al. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. Blood 2008;112(8):3052-6
66. Vos JM, Minnema MC, Wijermans PW, et al. Guideline for diagnosis and treatment of Waldenstrom's macroglobulinaemia. Neth J Med 2013;71(2):54-62
67. Ghobrial IM, Witzig TE. Waldenstrom macroglobulinemia. Curr Treat Options Oncol 2004;5(3):239-47
68. Hunter ZR, Branagan AR, Manning R, et al. CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia. Clin Lymphoma 2005;5(4):246-249
69. Ghobrial IM. Are you sure this is Waldenstrom macroglobulinemia? Hematology Am Soc Hematol Educ Program 2012;586-94
70. Gertz M.A. Waldenstrom macroglobulinemia: 2012 update on diagnosis, risk stratification and management. Am J Hematol 2012;87(5): 503-10
71. Kyle RA, Benson JT, Larson DR, et al. Progression in smoldering Waldenstrom macroglobulinemia: long-term results. Blood 2012;119(19):4462-6
72. Ghobrial IM, Fonseca R, Gertz MA, et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol 2006; 133(2):158-64
73. Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood 2001; 98(1):41-8
74. Dimopoulos MA, Hamilos G, Zervas K, et al. Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia. Ann Oncol 2003;14(8): 1299-305
75. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30(2):116-20
76. Dimopoulos M, Gika D, Zervas K, et al. The international staging system for multiple myeloma is applicable in symptomatic Waldenstrom's macroglobulinemia. Leuk Lymphoma 2004; 45(9):1809-13
77. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 2009;113(18):4163-70
78. Van Den Brand M, Van Krieken JH. Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic review. Haematologica 2013; 98(7):1003-13
79. Avet-Loiseau H, Garand R, Lode L, et al. 14q32 Translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30(2):153-155
80. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 2009; 27(1):120-6
81. Gertz M.A. Waldenstrom macroglobulinemia: is newer really better? Leuk Lymphoma 2010;51(12):2152-3
82. Treon SP, Patterson CJ, Kimby E, et al. Advances in the biology and treatment of Waldenstrom's macroglobulinemia: a report from the 5th International Workshop on Waldenstrom's Macroglobulinemia, Stockholm, Sweden. Clin Lymphoma Myeloma 2009;9(1):10-15
83. Anderson KC, Alsina M, Bensinger W, et al. Waldenstrom's macroglobulinemia/ lymphoplasmacytic lymphoma, version 2. J Natl Compr Canc Netw 2012; 10(10):1211-19
84. Owen RG, Kyle RA, Stone MJ, et al. Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop. Br J Haematol 2013;160(2):171-6
85. Blum W, Porcu P. Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome. Semin Thromb Hemost 2007; 33(4):350-4
86. Stone MJ, Bogen SA. Role of plasmapheresis in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2013;13(2):238-40
87. Rourke M, Anderson KC, Ghobrial IM. Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients. Leuk Lymphoma 2010;51(10):1779-92
88. Treon SP. How I treat Waldenstrom macroglobulinemia. Blood 2009;114(12): 2375-85
89. Dimopoulos MA, Zervas C, Zomas A, et al. Extended rituximab therapy for previously untreated patients with Waldenstrom's macroglobulinemia. Clin Lymphoma 2002; 3(3):163-6
90. Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol 2002;20(9):2327-33
91. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab and cyclophosphamide. J Clin Oncol 2007; 25(22):3344-9
92. Treon SP, Hanzis C, Tripsas C, et al. Bendamustine therapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011;11(1):133-5
93. Dimopoulos MA, Roussou M, Kastritis E, et al. Primary treatment of Waldenstrom's macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): final analysis of a phase II study. Blood (ASH Annual meeting abstracts) 2012;120(21): 438
94. Rummel MJ, Lerchenmuller C, Greil R, et al. Bendamustine-Rituximab Induction Followed by Observation or Rituximab Maintenance for Newly Diagnosed Patients with Waldenstro?m's Macroglobulinemia: Results From a Prospective, Randomized, Multicenter Study (StiL NHL 7-2008- MAINTAIN; ClinicalTrials.gov Identifier: NCT00877214). Blood (ASH Annual meeting abstracts) 2012;(21):2739
95. Treon SP, Hanzis C, Manning RJ, et al. Maintenance Rituximab is associated with improved clinical outcome in rituximab naive patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen. Br J Haematol 2011;154(3):357-62
96. Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol 2013;31(3):301-7
97. Leleu X, Soumerai J, Roccaro A, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J Clin Oncol 2009;27(2):250-5
98. Treon SP, Branagan AR, Ioakimidis L, et al. Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood 2009;113(16): 3673-8
99. Tam CS, Wolf M, Prince HM, et al. Fludarabine, cyclophosphamide and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer 2006; 106(11):2412-20
100. Tedeschi A, Benevolo G, Varettoni M, et al. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer 2012;118(2):434-43
101. Issa GC, Leblebjian H, Roccaro AM, Ghobrial IM. New insights into the pathogenesis and treatment of Waldenstrom macroglobulinemia. Curr Opin Hematol 2011;18(4):260-5
102. Treon SP, Patterson CJ, Munshi NC, Anderson KC. Proceedings of the Seventh International Workshop on Waldenstrom Macroglobulinemia. Clin Lymphoma Myeloma Leuk 2013;13(2):181-3
103. Sacco A, Aujay M, Morgan B, et al. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia. Clin Cancer Res 2011;17(7):1753-64
104. Treon SP, Tripsas CK, Sheehy P, et al. Prospective Phase II Clinical Trial of Carfilzomib, rituximab and Dexamethasone (CARD) in Patients with Symptomatic Waldenstrom's Macroglobulinemia (WM) [Abstract]. IWWM-7; 2012
105. Ghobrial IM, Gertz M, Laplant B, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010; 28(8):1408-14
106. Ghobrial IM, Boswell E, Banwait R, et al. Phase I trial of everolimus and rituximab or everolimus, bortezomib and rituximab in relapsed or relapsed/refractory waldenstrom's macroglobulinemia. Blood (ASH Annual meeting abstracts) 2011;118(21):2705
107. Ghobrial IM, Moreau P, Harris B, et al. A multicenter Phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia. Clin Cancer Res 2012;18(18):5043-50
108. Ghobrial IM, Roccaro A, Hong F, et al. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res 2010;16(3):1033-41
109. Treon SP, Soumerai JD, Branagan AR, et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008;112(12):4452-7
110. Treon SP, Soumerai JD, Branagan AR, et al. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res 2009;15(1):355-60
111. Sheeba KT, Donna MW, Michael W, et al. A Phase I Trial of Pomalidomide in Patients with Relapsed and/or Refractory Waldenstro?m's Macroglobulinemia (WM). IWWM-7 Session-9; 2012
112. Treon SP, Tripsas C, Warren D, et al. Phase I Study of Pomalidomide, Dexamethasone and Rituximab (PDR) in Patients with Relapsed or Refractory Waldenstrom's Macroglobulenima. Hematol Oncol (Abstract) 2013;31(S1):536
113. Grant S. Targeting Waldenstrom macroglobulinemia with histone deacetylase inhibitors. Leuk Lymphoma 2011;52(9): 1623-5
114. Ghobrial IM, Campigotto F, Murphy TJ, et al. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/ refractory Waldenstrom macroglobulinemia. Blood 2013;121(8):1296-303
115. Yang G, Xu L, Zhou Y, et al. Participation of BTK in MYD88 signaling in malignant cells expressing the L265P mutation in Waldenstrom's macroglobulinemia and effect on tumor cell with BTK-inhibitor PCI-32765 in combination with MYD88 pathway inhibitors [abstract]. J Clin Oncol 2012;30(Suppl):Abstract 8106
116. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31(1): 88-94